FDA's top vaccine regulator departs amid conservative criticism
'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' a spokesman for the Department of Health and Human Services (HHS) said in an emailed statement. 'We thank him for his service and the many important reforms he was able to achieve in his time at FDA.'
The spokesman did not say who would replace Prasad or provide a reason for his sudden departure.
Prasad's resignation comes amid mounting criticism from right-wing figures, including activist Laura Loomer and former Sen. Rick Santorum (R-Pa.), that coincided with a regulatory showdown with drug manufacturer over a gene therapy treatment for boys with Duchenne muscular dystrophy.
Loomer, an outside activist who has extraordinary sway with President Trump, has been attacking Prasad on social media and on her website in recent days. She's called him a 'saboteur' and 'trojan [sic] horse' of the administration's 'Make America Healthy Again' initiative.
'Far from being the reformist ally the Trump administration expected he may be, Prasad's liberal ideology, outspoken anti-Trump rhetoric, and deliberate actions to obstruct the President's deregulatory agenda make him a dangerous misfit in this critical position,' Loomer wrote on her website.
Her attacks were amplified by Santorum, who claimed in a post on social platform X that Prasad was 'destroying @POTUS legacy for helping patients.'
A few days later, a Wall Street Journal opinion column labeled Prasad 'a young disciple of Bernie Sanders' and accused him of 'scuttling potentially life-saving therapies.'
Prasad was named head of the FDA's Center for Biologics Evaluation and Research in early May as a replacement for Peter Marks, the longtime leader of division who resigned in March after clashing with HHS Secretary Robert F. Kennedy Jr.
Prasad's division has been involved in a regulatory dispute in recent weeks with Sarepta Therapeutics, the manufacturer of a gene therapy for Duchenne muscular dystrophy. The FDA forced Sarepta to stop all shipments of its treatment and halt clinical trials after the deaths of two patients who received the drug.
Prior to his role at FDA, Prasad had been an outspoken critic of the agency's initial decision to approve the treatment. The administration granted accelerated approval for Elevidys in June 2023 despite dubious evidence of its effectiveness to stop or reverse symptoms of the rare, fatal genetic disorder. To grant the approval, Marks unilaterally overrode multiple agency review teams that recommended against it.
On Monday, the agency issued a statement partially reversing itself, removing the pause for patients who can still walk.
Prasad was a key ally of FDA Commissioner Marty Makary, with whom he recently worked to narrow the approval for updated COVID-19 vaccines.
Instead of recommending the shots for everyone, Prasad said they will only be approved for use in adults 65 and older and people at high risk for severe disease.
In an interview with Politico published last weekend, Makary defended Prasad.
'There's not a political bone to his body,' Makary said. 'He's an impeccable scientist, I think one of the greatest minds of our generation.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
19 minutes ago
- The Hill
Trump slams WSJ amid Epstein lawsuit, claiming it's ‘China centric'
President Trump on Thursday slammed The Wall Street Journal's editorial board for routinely criticizing his trade policy with 'China-centric' rhetoric. 'The reason that The Wall Street Journal Editorial Board is always negative on 'TRUMP,' and the Hundreds of Billions of Dollars we're bringing into our Country through Tariffs, numbers that the U.S.A. has never seen before, is because they are China centric or, at a minimum, Globalists, and they would rather see China and the World, for reasons unknown, 'WIN, BABY, WIN,'' the president wrote in a Truth Social post. 'If the United States were not able to charge Tariffs to other Countries, it would be Economically defenseless and, of no further force or effect,' he added. In recent months, the Journal's editorial board has published a series of op-eds critiquing the president's fluctuating trade rates while alleging measures that violate federal law. 'He's treating the North American economy as a personal plaything, as markets gyrate with each presidential whim,' the board wrote in March. 'It's doubtful Mr. Trump even has the power to impose these tariffs, and we hope his afflatus gets a legal challenge.' Months later, the outlet published an article detailing a birthday letter allegedly signed by the president and sent to convicted sex offender Jeffrey Epstein. Trump denied the correspondence and responded with a lawsuit naming Rupert Murdoch, the Journal and NewsCorp, accusing the paper of relying on 'sources that don't even exist.' As the legal battle plays out in court, the president has continued to reject disapproval from the conservative outlet. 'The only thing that can destroy our Country are Crooked, Radical Left Judges, of which there are many!' Trump wrote on Thursday.
The Hill
19 minutes ago
- The Hill
Questions loom over potential Trump-Putin summit
Trump has grown increasingly frustrated with Putin in recent months as Russia pounds Ukraine despite U.S. calls for a pause in the fighting. The administration on Wednesday announced tariffs on India over its purchases of Russian oil, and additional sanctions on Russia are expected Friday. Much is still unknown about the meeting, including when, where — and even whether — it will happen. Both the White House and the Kremlin have indicated the meeting will take place soon, potentially as early as next week. But officials did not offer details on where it would take place, how long it would last or who would be involved. Trump told European leaders on a call on Wednesday that his idea was to meet with Putin and then have a trilateral meeting with Putin and Ukrainian President Volodymyr Zelensky. It was unclear if all parties would agree to such a setup, or who else might attend. Trump told reporters Thursday that Zelensky's attendance was not a prerequisite for him to meet with Putin. Possible venues could include Turkey, which has served as a mediator for U.S.-Russian prisoner swaps. The United Arab Emirates has also mediated between Russia and Ukraine for prisoner swaps. Qatar is a mediator the U.S. has relied on heavily in negotiating between Israel and Hamas and between warring parties in Africa. One key piece of any potential summit is Ukraine's role. Trump indicated to European leaders that his idea would be to meet with Putin, then host a meeting with Putin and Zelensky. The Kremlin had earlier dismissed the possibility of a meeting between Putin and Zelensky unless negotiators had reached the final stages of a deal to end the war. Zelensky has not publicly commented on a potential meeting with Putin, and such a meeting would be the first time the two leaders have come face-to-face since the war began in 2022. But he has been adamant that there should be no decisions about Ukraine without Ukrainian input. Such a high-stakes meeting could yield a historic diplomatic win for Trump if he stops the war — but it also carries risks for all parties involved. Trump has repeatedly demurred on whether Putin is stringing him along, and an in-person meeting could buy the Russian leader more time without producing concrete results toward a ceasefire in Ukraine. White House officials have indicated they are going into the potential meeting with eyes open about Putin's lack of commitments thus far.
Business Insider
20 minutes ago
- Business Insider
Are Semiconductors a 'Sell' After Trump Tariffs?
Trump's 100% tariff on semis and what it means… what McDonald's earnings say about the U.S. consumer… checking in on Jonathan Rose's NioCorp trade… a laundry list of winners VIEW IN BROWSER In yesterday's Digest, we reported on President Trump's plan to unveil new tariffs on semiconductor companies 'within the next week or so.' Well, that 'week or so' turned into about an hour. Shortly after that Digest hit your inbox, Trump confirmed plans for a 100% tariff on imported semiconductors, with one big caveat – companies that manufacture chips in the U.S., or commit to doing so, will be exempt. Apple's CEO Tim Cook stood by Trump during the announcement after Apple pledged an additional $100 billion in U.S. investment (bringing its total domestic commitment to about $600 billion) and received that exemption. So, what does this mean? And what's the investment step? The headline '100% chip tariff' is dramatic. But the actual policy functions more like a policy lever than a full‑blown blockade. This isn't a death knell to the overall AI/semiconductor story or AI profits (which is why the tech sector isn't plummeting as I write Thursday). But neither is it a nothingburger. As to how to respond, here are three guidelines: Prioritize companies investing in U.S. manufacturing – firms such as TSMC, Samsung, Nvidia, and GlobalFoundries are expanding their U.S. operations and are in a good position to benefit from exemptions Maintain your core AI holdings – the new tariffs don't undermine long-term demand for semiconductors. Hold your top-tier AI plays Look past the headlines for long-term opportunity – if more drama and downward volatility is ahead of us, look for favorable entry points on AI/semi leaders selling off in sympathy Bottom line: Though the headlines sound frightening, this is ultimately bullish for well‑positioned AI players. Yesterday, McDonald's beat earnings expectations, but… While Wall Street applauded the numbers, the company's tone was cautious for one main reason… Weakness among low-income consumers. From CEO Chris Kempczinski: Reengaging the low-income consumer is critical, as they typically visit our restaurants more frequently than middle- and high-income consumers. This bifurcated consumer base is why we remain cautious about the overall near-term health of the U.S. consumer. Longtime Digest readers will recognize this 'bifurcated consumer base' and recall the term we've used within this broader conversation: the 'Technochasm.' There's a growing divide today between the 'haves' and 'have nots' – both in the market and in our society. One of the most influential factors driving this growing divide is wealth generated from investments in cutting-edge technology and artificial intelligence, something our experts have coined, 'The Technochasm.' This bifurcation – strength from higher earners, fragility among lower-income households – is becoming a recurring theme in earnings reports across industries. And it's a valuable clue into the true health of the U.S. consumer. This is especially important in the wake of last Friday's jobs report – the weakest in over a year – and Tuesday's ISM data, which caused legendary investor Louis Navellier to say: We are teetering on a recession here, folks, and I don't like to use that R word, but that's what's happening. Can high-income earners spend us out of a recession? I've been a part of some interesting conversations with InvestorPlace analysts that tackle whether higher-income consumers can spend enough to offset the tightening we're seeing from lower-income households. There's some evidence suggesting this has been happening. For example, earlier this year, credit card data showed that upper-income households were spending regularly, particularly on experiences like travel, fine dining, and entertainment. Here's CNBC from the spring: Lower-income earners are reining in their transactions to focus on essentials, while the wealthy continue to spend freely on perks including dining out and luxury travel, according to first-quarter results from U.S. credit card lenders… For instance, at Synchrony, which provides store cards for retail brands including Lowe's and T.J. Maxx, spending fell 4% in the first three months of the year… That compares to a 6% spending jump at American Express and a similar rise at JPMorgan Chase, both of which cater to wealthier users with higher credit scores than Synchrony. AmEx said its customers spent 7% more on dining and 11% more on first class and business class airfare than a year earlier. These consumers are benefiting from rising asset values, higher interest income, and – thanks to the AI boom – significant gains in tech-heavy investment portfolios. But we're starting to see signs of fatigue Let's jump to Fortune from last week: More than half (58%) of six-figure earners no longer feel financially successful, according to a recent report from Clarify Capital… More than seven in 10 of these high earners are now being forced to shop at discount grocery chains to save cash. Around 74% also say they're cutting back on dining out, 54% are skimping out on entertainment, 51% are getting thrifty with buying clothes, 49% are scaling back their subscriptions, and 49% are spending less on travel… About 85% of six-figure workers say they feel stressed and anxious due to increased living costs. Fortune goes on to report that the delinquency rate among high-income borrowers has surged 130% over the last two years. As to the investment implications, there are many ways we can take this Let's briefly walk through four options. Invest in the companies at the forefront of the technologies that will continue to explode the Technochasm Clearly, that's AI. But as we've been profiling here in the Digest, the latest evolution is 'Physical AI' (think robots/humanoids). On Monday through Wednesday, we brought you interviews from Louis Navellier, Eric Fry, and Luke Lango detailing this opportunity. And they just released a new portfolio of Physical AI leaders in their AI Revolution Portfolio investment service. Regardless of how you do it, giving your portfolio at least some exposure to cutting-edge AI is imperative. Focus on fundamentally superior companies that are growing their earnings, despite a broader consumer slowdown This has been the cornerstone of Louis' market approach for decades. Earlier this week, in the same Flash Alert market update in which Louis warned of a potential recession, he also congratulated his Growth Investor subscribers on three earnings wins from earlier this week. Here's how those stocks have performed since Tuesday: AXON: +13% KGC: +11% PLTR: +9% As Louis loves to say: 'earnings are working.' Trade companies successfully catering to lower-income Americans Lower-income shoppers are still buying from certain retailers, causing Wall Street to push up prices. Our hypergrowth expert Luke Lango is in one such retailer in Breakout Trader – Dollar Tree (DLTR). After opening the trade in late-April, they're sitting on 31% gains. These lower-income trades aren't necessarily 'hold forever' stocks, but for however long cost-conscious shoppers help drive their prices higher, stick with bullish momentum. Refresh yourself on the valuations of every stock you own If even higher-income consumers are beginning to pull back, earnings are likely to be next. And when earnings fall, eventually, stock prices do too – especially those priced for perfection. So, refamiliarize yourself with the valuation of each stock you hold. Make sure you're comfortable. (If you missed Eric's recent free research report on which expensive AI stocks he's selling today – and which stocks he's recommending to replace them – you can check it out right here.) Coming full circle to McDonald's… Its earnings report is a snapshot of the Technochasm in action. Yes, certain consumers are still spending. But for many – especially at the lower end of the income spectrum – the strain is becoming undeniable. Bottom line: When McDonald's says it's having to 'reengage' its most loyal customers through cheaper meals, we should take notice. That's a macro warning. Checking in on Jonathan Rose's NioCorp trade Back in July, we put a new speculative trade on your radar – NioCorp Developments (NB) – thanks to a heads-up from veteran trader Jonathan Rose. Jonathan had just closed a 700% win on rare earth play MP Materials. And he had recently recommended a trade on NB as another early-stage name riding the same wave: U.S. demand for critical minerals tied to defense, energy, and the AI boom. At the time, we emphasized caution. As with any speculative trade, risk mitigation is key because volatility was likely. To that end, Jonathan had recommended a defined-risk trade. Well, the very next day, NB traded sharpy lower. Jonathan explained that the selloff was driven by a capital raise – standard behavior for small-cap names funding their growth. He wasn't concerned for the trade. If you took advantage of that selloff, congrats Fast-forward to today, and NB is soaring, rapidly approaching its pre-capital-raise high. It's up 54% from its late-July low, so if you bought on that weakness, congrats, you're likely sitting on double-digit gains. Better still, even higher prices appear on the way… A major new catalyst for growth On Tuesday, we learned that the U.S. Department of Defense has awarded up to $10 million to NioCorp's Elk Creek Resources unit to support its domestic production of scandium – a rare earth metal critical for advance defense and aerospace systems. This is a big deal. Virtually the entire global scandium supply comes from China, Russia, and Ukraine. The U.S. hasn't mined scandium since 1969 – until now. NioCorp's Elk Creek project is also sitting on high-value niobium and titanium, both essential for hypersonic missiles and other military applications. The company already has binding long-term deals in place for 75% of its planned niobium output, and it just inked its largest scandium deal ever. From CEO Mark Smith: This is a grant, not an investment. It shows strong U.S. government backing and how critical niobium and scandium are for defense. In short, this is no longer just a speculative story; it's becoming big business, with real government backing. We'll repeat ourselves from our July 16 Digest: If you're looking for what could be the market's next major overnight winner, consider yourself in the loop. Before we sign off, a quick 'congratulations' to Jonathan's Advanced Notice subscribers They're on a roll right now. Since March, here are their closed trade results: 18 trades: 14 winners, 4 losers 113.73% average return across all closed positions 169.91% average return across the winning positions 77.8%-win rate Average trade hold period: 36 days As we've said many times, Jonathan is one of the best traders in the biz. To get a better sense for how and why, join him for his free Masters in Trading Live broadcasts at 11:00 a.m. Eastern time every day the market is open. They're a great way to deepen your understanding of trading – and to see firsthand the strategies Jonathan uses to capture triple-digit gains, sometimes in just days.
